Lionheart Health, Inc., a leader in bioelectric regeneration and longevity biotechnology, announced the filing of a non-provisional U.S. patent for its Bioelectric-Enhanced Klotho Nanoflowers, a platform technology designed to reverse aging and extend healthspan. The patent covers a therapeutic system that integrates nanoflower-format nanoparticles, bioelectric signaling sequences, and Klotho-modulating biologics to target cellular and mitochondrial drivers of aging.
The platform utilizes engineered nanoflowers—flower-shaped hybrid nanoparticles capable of upregulating Klotho, a longevity-associated protein that improves brain, kidney, cardiovascular, and metabolic health. These nanoflowers restore mitochondrial function by enhancing ATP production and reducing oxidative stress, deliver targeted agents such as peptides, plasmids, mRNA, and CRISPRa activators, act as nanozyme catalysts to reduce reactive oxygen species, and enhance regenerative signaling when activated by precise bioelectric patterns.
According to Howard J. Leonhardt, Founder and CEO of Lionheart Health, this invention represents the convergence of bioelectric signaling, nanomedicine, and Klotho modulation. The nanoflowers are engineered to respond to Lionheart's proprietary bioelectric stimulation sequences, which increase cellular uptake, activate intracellular pathways, and amplify biological performance. The bioelectric signals open ion channels, improve endocytosis, direct nanoflowers toward mitochondria, and trigger therapeutic payload release. Klotho expression increases due to nanoflower-delivered genetic or peptide payloads and bioelectric activation of promoter and epigenetic pathways, demonstrating a combined therapeutic benefit.
The system is designed for system-wide healthspan improvement, including mitochondrial biogenesis via activation of PGC-1α, NRF1/2, and TFAM; reduction of cellular senescence through lower oxidative stress; and stabilization of biological age by combining mitochondrial repair with Klotho enhancement. Klotho is widely recognized as a key longevity molecule, and decreased levels are associated with accelerated aging, cognitive decline, inflammation, vascular calcification, kidney dysfunction, and frailty. Preclinical models have shown benefits in brain aging, muscle repair, cardiac healing, kidney protection, and metabolic health when Klotho expression is increased.
Dr. Leslie Miller, Chief Medical Officer and former President of the International Society for Heart and Lung Transplantation, noted that bioelectric-enhanced Klotho nanoflowers provide a programmable, multi-modal tool to address root causes of aging such as declining energy production, rising inflammation, and loss of regenerative capacity. The patent filing adds to Lionheart Health's growing intellectual property portfolio, which includes bioelectric-controlled protein expression, stem-cell mobilization, mitochondrial restoration, and Klotho-based gene therapy and peptide therapeutics.
Lionheart Health is preparing for expanded clinical evaluation within its network of Lionheart Longevity & Wellness Licensed Clinics in the U.S. and abroad. The company also plans to integrate the technology into its XPRIZE Healthspan competition program. More information is available at www.LionheartHealthStim.com and www.LionheartLongevity.com.
